NonStandard Stability Protocols May Receive FDA Special Assessment Review
Executive Summary
General sponsor inquiries regarding the adequacy of a protocol should not be addressed under FDA's special protocol assessment provisions, the agency said in a Feb. 8 draft guidance on special protocol assessment.